P-1499. Patient Characteristics and Clinical Outcomes Associated with Meropenem/Vaborbactam Treatment in Carbapenem-Resistant Enterobacterales Pneumonia
Abstract
Abstract Background Carbapenem-resistant Enterobacterales (CRE) are a major public health threat due to increasing prevalence and limited effective treatment options. Meropenem/vaborbactam (M/V) is a beta-lactam/beta-lactamase inhibitor agent designed to treat CRE. There is a paucity of data related to patient characteristics and associated outcomes with the utilization of M/V in pneumonia due to CRE. The objective of this study was to describe real-world experience with M/V in this setting. Methods This is a retrospective, observational, multicenter, cross-sectional study of patients ≥ 18 years old who received M/V for ≥ 72 hours for clinically-diagnosed hospital-acquired (HAP) or ventilator-associated pneumonia (VAP) due to CRE between 6/2020-2/2024. The primary outcome was clinical success, defined as resolution or improvement in signs/symptoms of infection and without the need for additional therapy. The secondary outcomes included 30-day mortality, 30-day microbiologic recurrence, 30-day symptomatic recurrence and adverse drug reaction(s). Results Sixty-two patients were included from six U.S. medical centers. The mean age (standard deviation [SD]) was 58.2 (15.4) years; patients were predominantly male (71.0%) and Caucasian (58.1%). At time of culture collection, the mean (SD) APACHE II score was 22.1 (7.8) and most patients (78.0%) were admitted to the intensive care unit. Klebsiella pneumoniae was the predominant species isolated in culture (43.5%). Notably, 65.6%…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.